Regeneron (REGN) Tops Q4 EPS by $5.35
Regeneron (NASDAQ: REGN) reported Q4 EPS of $23.72, $5.35 better than the analyst estimate of $18.37. Revenue for the quarter came in at $4.95 billion versus the consensus estimate of $4.42 billion.
2022 Financial Guidance(4)
The Company's full year 2022 financial guidance consists of the following components:
GAAP | Non-GAAP(1) | |||
R&D | $3.170 billion–$3.400 billion | $2.800 billion–$3.000 billion | ||
SG&A | $1.890 billion–$2.030 billion | $1.650 billion–$1.770 billion | ||
Gross margin on net product sales(5) | 89%–91% | 90%–92% | ||
COCM(6) | $750 million–$830 million | * | ||
Other operating (income) expense, net | ($60) million–($80) million | * | ||
Capital expenditures | $650 million–$730 million | * | ||
Effective tax rate (ETR) | 12%–14% | 13%–15% | ||
* GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been or are expected to be recorded. | ||||
For earnings history and earnings-related data on Regeneron (REGN) click here.